A Phase I, Cross-over Study Comparing the Relative Bioavailability of Laroprovstat Plus Ezetimibe Fixed Combination Drug Products Versus Their Single Therapy Products in Healthy Adults

Inclusion Criteria

• Inclusion Criteria:
• - Healthy male and female participants aged 18 to 55 years at the time of signing consent.
• - All females must have a negative pregnancy test at the Screening Visit and on admission to the study site.
• - Females of childbearing potential must not be lactating and if heterosexually active must agree to use an approved method of highly effective contraception.
• - Have a Body mass index (BMI) between 18 and 30 kg/m2 inclusive and weigh at least 50 kg.
• Exclusion Criteria:
• - History of any clinically important disease or disorder.
• - History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
• - History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity to drugs with a similar chemical structure or class to laroprovstat or ezetimibe.
• - Treatment with any lipid lowering therapy or laroprovstat within the 3 months prior to the Screening Visit.
• - Treatment with drugs for reduction or inhibition of Proprotein convertase subtilisin/kexin type 9 (PCSK9) within the last 12 months prior to the Screening Visit or inclisiran at any time.